Histogen (HSTO) Peer Comparison

$0.03

$0.00 (0.00%)

As on 28-Jan-2025 09:30EDT

Market cap

$0 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Market cap ($ Mln)	0	20	0
Revenue ($ Mln)	0	--	--
Net Profit ($ Mln)	-12.40	-27.73	-31.57
Net Margin (%)	-65,278.95	-693,325.00	--
RoE (%)	-147.67	-240.85	--
Price to Earnings	--	--	--
Price-To-Book	0.02	1.32	2.29

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Operating Revenue	3.77	0.00	0.00
Cost of Revenue	0.14	0.03	2.73
Gross Profit	3.77	-0.03	-2.73
Operating Expenses	14.41	11.42	38.26
Operating Profit (EBIT)	-10.64	-19.63	-38.26
Other Income	--	--	--
Profit before Tax	-10.64	-13.97	-39.75
Provision for Tax	-0.16	-7.85	0.01
Profit after Tax (Net Income)	-10.48	-6.12	-39.76
Minority Interest	--	--	--
Consolidated Profit	-11.11	-15.28	-39.76

Liabilities ($ Mln)

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Shareholder's Funds	14.41	21.75	-0.90
Minority Interest	--	--	--
Non-Current Liabilities	4.46	0.71	10.35
Current Liabilities	1.23	11.78	13.49
Total Liabilities	19.07	33.53	22.94

Assets ($ Mln)

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Non-Current Assets	5.62	0.00	4.50
Current Assets	13.46	33.53	18.45
Total Assets	19.07	33.53	22.94
Total Debt*	4.63	0.07	14.88
Net Current Assets	12.22	21.75	4.95

Cashflow ($ Mln)

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Cash From Operating Activities	-9.68	-11.71	-28.93
Cash Flow from Investing Activities	-0.22	-0.59	-1.18
Cash from Financing Activities	3.32	0.03	5.28
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
ROCE (%)	-46.61	-33.58	-132.08
ROE (%)	-58.89	-33.65	-221.99
ROA (%)	-45.26	-24.30	-107.60
EBIT Margin (%)	--	--	--
Net Margin (%)	-278.08	--	--
Cash Profit Margin (%)	--	--	--

Growth Ratios

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Revenue Growth (%)	3.10	--	-1.00
EBIT Growth (%)	--	--	--
Net Profit Growth (%)	27.24	59.83	1.43
EPS Growth (%)	--	--	0.18
Book Value Growth (%)	--	--	--

Valuation Ratios

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Price / Earnings	--	--	-0.66
Price / Book Value	--	--	-29.19
Dividend Yield (%)	--	--	--
EV/EBITDA	0.75	2.93	-0.71
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Debt to Equity	0.32	0.00	-16.55
Short term debt to equity ratio	0.02	0.00	-5.04
Current Ratio	10.90	2.85	1.37
Quick Ratio	10.58	--	--
Interest Coverage	-10,643.00	-5.21	-25.66

Operating Efficiency Ratios

	Histogen (HSTO)	Neurobo Pharmaceuticals Inc (NRBO)	Better Therapeutics Inc (BTTX)
Debtors to sales (%)	2.63	--	--
Asset Turnover	0.16	0.00	0.00
Receivable days	12.79	--	--
Inventory Days	2,774.60	--	--
Payable days	2,315.42	10,031.33	305.02
Cash Conversion Cycle	471.96	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly